Abstract 12157: Drug Eluting Stents with Microporous Polymeric Covering as a Scaffold for Acquisition of Extremely Thin Noeintimal Lying without Disturbing Branching Vascular Flow
Objective: As new generation of drug eluting stents, we developed microporous polymeric-covered stents, whose design concept was utilization of covering for a scaffold for extremely thin neoinitimal lying. The effectiveness was demonstrated in this study for long-term animal experiments.
Methods and Results: Two types of covered stents based on different stent platforms of self-expandable stents (Luminexx from Bard Co.; 5 mm x 20 mm) and balloon-expandable stents (Momo from Japan Stent Technology. Co.; 3 mm x 20 mm) were prepared in three steps, that is 1) dip-coating of polyurethane for covering, 2) laser-induced microporing, and 3) drug coating with argatroban. The stents had structural advantage with flat luminal surface impregnating strut completely into the cover film. The stents were placed at carotid or subclavian arteries of beagle dogs or rabbits. Even at 1 month of implantation (n=5) the luminal surface was fully endothelialized. Extremely thin neointima (n=19, thickness; 187 ± 39 μm) was observed at 1 year of implantation, which was about half of that in non-covered bare stents. The thin and stable neointima continued up to 3 year of implantation (n=15). The covered stents could maintain the branching micro-vascular flow perfectly due to microporing of cover film. Argatroban had strong anti-thrombogenic and anti-inflammation potentials.
Conclusions: Argatroban-loaded microporous covered stents developed here were effective for in short-term lying of extremely thin neointima with long-term highly reliability.
- © 2010 by American Heart Association, Inc.